About
Small Molecules Targeting RAS-driven Cancers
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Clinical Trials (15)
View allTotal Trials
15
As Lead Sponsor
9
As Collaborator
6
Total Enrollment
965
By Phase
PHASE1: 13EARLY_PHASE1: 1PHASE1/PHASE2: 1
By Status
UNKNOWN: 9RECRUITING: 4ACTIVE_NOT_RECRUITING: 2
Clinical Trials Pipeline15 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06715124Lead Sponsor
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
PHASE1Recruiting
237 participants
Started: Jan 14, 2025 · Completed: Jan 2, 2029
NCT06428500Lead Sponsor
QTX3046 in Patients With KRAS G12D Mutations
PHASE1Active, not recruiting
240 participants
Started: May 30, 2024 · Completed: Jul 1, 2027
NCT06227377Lead Sponsor
QTX3034 in Patients With KRAS G12D Mutation
PHASE1Recruiting
250 participants
Started: Feb 5, 2024 · Completed: Apr 1, 2027
NCT07074496Collaborator
Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
EARLY_PHASE1Active, not recruiting
20 participants
Started: Jan 1, 2024 · Completed: Jul 1, 2028
NCT05776407Collaborator
Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma
PHASE1/PHASE2Unknown
12 participants
Started: May 31, 2023 · Completed: Nov 30, 2024
Locations (1)
Headquarters
South SF, CA, United States
Map
Loading map...